...
首页> 外文期刊>P & T: a peer-reviewed journal for formulary management >Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing: The Pressure Is on P&T Committees to Monitor Utilization.
【24h】

Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing: The Pressure Is on P&T Committees to Monitor Utilization.

机译:卫生计划和药品公司将脚趾浸入基于价值的定价中:P&T委员会面临监督使用压力。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The agreement between Harvard Pilgrim and Amgen on a "pay for performance" deal involving evolocumab could encourage other manufacturers, health plans, and policy-makers to press for value-based pricing as drug costs continue to escalate.
机译:哈佛朝圣者与安进(Amgen)之间就evolocumab达成的“绩效补偿”协议,可能会鼓励其他制造商,卫生计划和政策制定者在药品成本持续上涨的情况下,推动基于价值的定价。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号